Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

Hepatology

Volumn 53, Issue 1, 2011, Pages 7-13

  Yu, Ming Lung ^a,b,d   Huang, Chung Feng ^a,d   Huang, Jee Fu ^b,d,f   Chang, Ning Chia ^b,e   Yang, Jeng Fu ^d,e   Lin, Zu Yau ^b,d   Chen, Shinn Cherng ^b,d   Hsieh, Ming Yuh ^b,d   Wang, Liang Yen ^b,d   Chang, Wen Yu ^b,d   Li, Yi Ning ^c   Wu, Mei Shin ^c   Dai, Chia Yen ^b,d   Juo, Suh Hang Hank ^c,e   Chuang, Wan Long ^b,d  

^a KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^b Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Internal Medicine   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78649320722     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23976     Document Type: Article

References (35)

1. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19( Suppl 1): 57-65.
2. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-559.
3. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617.
4. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134.
5. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004; 40: 1260-1265.
6. Huang C-F, Yang J-F, Huang J-F, Dai C-Y, Chiu C-F, Hou N-J, et al. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol 2010; 25: 758-765.
7. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
10. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-264.
11. Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148: 120-127.
12. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
13. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
14. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
15. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. Gastroenterology 2010; 139: 120-129.
16. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an interleukin-28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
17. Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74(pt 11): 2385-2390.
18. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
19. International HapMap project. Accessed September 2010.
20. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
21. Tang J, Kaslow RA. Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection. Pharmacogenomics J 2004; 4: 171-174.
22. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86: 23-32.
23. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
24. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854.
25. Schiffman M. J Hepatol 2009; 50(Suppl): S237.
26. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. HEPATOLOGY 2008; 47: 1884-1893.
27. Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. HEPATOLOGY 2009; 50: 369-377.
28. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336-345.
29. Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 2010; 17: 139-147.
30. Grasso A, Malfatti F, De Leo P, Martines H, Fabris P, Toscanini F, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51: 984-990.
31. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105: 1970-1977.
32. Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, et al. Ribavirin dosage in HCV genotypes 2 and 3 patients completing short therapy with peg-interferon alfa-2b and ribavirin. Aliment Pharmacol Ther 2010; 31: 1346-1353.
33. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
34. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
35. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.